Assembly Biosciences
A clinical-stage biopharmaceutical company with therapeutic clinical candidates capable of improving the lives of chronic hepatitis B virus (HBV) patients around the world.
Assembly Biosciences is leading the development of therapeutics for viral diseases, including pursuing finite and potentially curative therapies for people living with HBV.
The USA-based company is advancing a portfolio of more potent, next-generation core inhibitor drug candidates that aim to break the complex viral replication cycle of HBV, and research programs focused on the discovery of additional novel antiviral mechanisms for HBV and other viral diseases.
Latest Assembly Biosciences News & Features
17 October 2023
26 May 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze